ScinoPharm Taiwan, Ltd. (TPE:1789)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
20.60
+0.25 (1.23%)
Apr 28, 2026, 1:30 PM CST
11.05%
Market Cap 16.29B
Revenue (ttm) 3.16B
Net Income (ttm) 136.95M
Shares Out 790.74M
EPS (ttm) 0.17
PE Ratio 121.18
Forward PE n/a
Dividend 0.29 (1.43%)
Ex-Dividend Date Jul 3, 2025
Volume 675,539
Average Volume 1,159,109
Open 20.60
Previous Close 20.35
Day's Range 20.20 - 20.60
52-Week Range 16.25 - 29.10
Beta 0.54
RSI 43.78
Earnings Date May 4, 2026

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd., a pharmaceutical company, provides active pharmaceutical ingredient (API) development and manufacturing and injectable solutions in Taiwan, rest of Asia, Europe, and the Americas. It offers small molecules, peptide drugs, and steroids; drug products for anticancer, thromboembolic disorders, and osteoporosis; and contract analytical testing, sterile injectables contract manufacturing, and small molecules and peptide contract development and manufacturing organization services. The company was incorporated in 1997 and is ... [Read more]

Sector Healthcare
Founded 1997
Employees 540
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 1789
Full Company Profile

Financial Performance

In 2025, ScinoPharm Taiwan's revenue was 3.16 billion, a decrease of -7.13% compared to the previous year's 3.41 billion. Earnings were 136.95 million, a decrease of -59.64%.

Financial Statements

News

ScinoPharm Wins First FDA Approval With Glatiramer Acetate Injection For Multiple Sclerosis

(RTTNews) - ScinoPharm Taiwan (TWSE: 1789) today announced that the U.S. FDA has approved its Glatiramer Acetate Injection, a generic version of Teva's Copaxone, for the treatment of adult patients wi...

4 months ago - Nasdaq